Iron Deficiency Anemia
Conditions
Interventions
Study group: Replacement with ferric carboximaltose 1000 mg diluted in saline solution 0.9% 250ml, in a single intravenous infusion for 15 minutes. (n=203)
Control group: Replacement with iron hydrox
Drug
D01.490
Sponsors
Universidade Ceuma
Universidade Ceuma
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients 18 years of age or older; diagnosis of solid malignancies detected in an anatomopathological examination; presenting hemoglobin levels below 12 g / dl in females or 13 g / dl in males
Exclusion criteria
Exclusion criteria: Pregnant patients; in palliative care; with previous history of hypersensitivity to any of the iron formulations of this study; lack of adequate venous access to the infusion of the drug; refusal to continue the indicated supplementation; worsening of the oncological condition that compromises the response to treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find an increase in hemoglobin, verified by the hemogram, based on an increase of at least 10% in the pre- and post-intervention measurementsoglobin | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to find an increase in hematocrit, verified by the hemogram, from the finding of an increase of at least 10% in the pre- and post-intervention measurements;It is expected to find an increase in hematimetry, verified by the hemogram, based on an increase of at least 10% in the pre- and post-intervention measurements | — |
Countries
Brazil
Contacts
Public ContactEduardo;Tula Figuerêdo;de Siqueira
Universidade Ceuma;Universidade Ceuma
Outcome results
None listed